You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. A2A receptor blockade for sepsis

    SBC: Purine Pharmaceuticals Inc.            Topic: NIAID

    SUMMARY Sepsis is a clinical syndrome that complicates severe infectionSepsis remains the leading cause of morbidity and mortality in critically ill patientsThere are no specific FDA approved medicines for the treatment of sepsisCurrent concepts of the pathophysiology of sepsis suggest that organ failure and mortality in sepsis are caused by inappropriate regulation of the immune systemThis manife ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. AC5 Inhibitor for Obesity

    SBC: VASADE BIOSCIENCES, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop a drug that will be therapeutic for obesity and diabetes and improve exercise tolerance. Obesity, diabetes and exercise are inextricably linked such that an agent that improves exercise tolerance or prevents obesity or the development of diabetes will likely have a therapeutic role in all three conditions. Obesity is a gl ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. A cost-effective bioreactor to advance functional tissue engineering of cartilage

    SBC: Apex Biomedical Company, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the leading cause of chronic disability in the United States. A clinical goal in the treatment and prevention of OA is to develop replacement cartilage using tissue engineering (TE) technologies. Although TE cartilage presently lacks the mechanical stability of native cartilage, studies have demonstrated that mechanical stability can be e ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  5. A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinoma

    SBC: Avenzoar Pharmaceuticals, Inc.            Topic: 102

    ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Advancing clemizole for hepatitis C: towards a pre-IND package

    SBC: EIGER GROUP INTERNATIONAL, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Over 150 million people worldwide are infected with the hepatitis C virus (HCV), which is an important cause of chronic liver disease. Current therapies are inadequate. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We recently discovered and genetically validated a new target within the HCV non-structural protein NS4B, consist ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. A Home Exercise Program (DVD) for Women with Infants and Young Children

    SBC: KLEIN BUENDEL, INC            Topic: NIDA

    DESCRIPTION (provided by applicant): Becoming a mother is a significant transition in a woman's life. This transition can precipitate major changes in health behaviors, like physical activity. Once a woman has a child she is much less likely to participate in regular, moderate to vigorous physical activity compared to women without children. Thus, new mothers are at risk for future weight gain and ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  8. AHTP-comet: development of an automated, high throughput comet assay system

    SBC: Engineering Resources Group, Inc            Topic: NIEHS

    PROJECT SUMMARY Genomic instabilityinduced by DNA damageand partly mitigated by DNA repair and antioxidantsplays a critical role in the pathogenesis of many major human diseasessuch as neurodegenerationcancer and cardiovascular diseasetogether with agingThere is a critical need for automated assays that can perform these assessmentsand bring them into greater routine usewhich will help advance our ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Allergen???Fc-gamma1 proteins to treat food allergy

    SBC: TUNITAS THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop and commercialize a novel approach for allergen specific immunotherapy as treatment for severe food allergy. Food allergy affects about 3.5% of the US population and 6% to 8% of young children. It is clearly on the rise. Peanut allergy, which affects around 1% of the population, is among the most severe food allergies, r ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. A microfluidic device for blood analysis in neonates

    SBC: Sersense Inc            Topic: NICHD

    ABSTRACT Premature infants are frequently at risk of infectionjaundice and hypoglycemiaconditions monitored by analysis of blood for c reactive proteinCRPbilirubin and glucose respectivelyTypicallymL of blood is drawn each time an infant is tested with multiple blood draws happening over the course of daysGiven that total blood volume of in premature infants ismLup toof blood volume may be lost du ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government